HRT Black Box Warning Removed: What It Means for You

For more than two decades, menopause hormone therapy labels carried the FDA's most serious warning: a "black box" about heart disease, stroke, breast cancer and dementia. For many women, that box was the reason they never tried hormones, even for symptoms that were wrecking their sleep.

That warning is going away. On November 10, 2025, the FDA announced it would remove most of the boxed warning from menopausal hormone therapy (MHT, often called HRT). On February 12, 2026, it approved the first batch of rewritten labels. Other product labels are still being updated.

This article covers the news itself: what the FDA changed, what it left in place, why the old warning existed, why some experts think the FDA went too far, and who is a reasonable candidate for HRT today. If you want help choosing between pills, patches, gels and vaginal products, see our companion guide, How to Know Which HRT Plan Is Right for You.

Table of Contents

What the FDA actually changed

A boxed warning is the most prominent safety statement the FDA puts on a drug label. It sits in a black border at the top of the prescribing information. Moving a risk out of the box does not erase the risk. It moves it into the regular Warnings and Precautions section, where it sits alongside other risks.

Here is what changed, based on the FDA's announcements and the new labels:

• Removed from the boxed warning: statements about cardiovascular disease, breast cancer and probable dementia.
• Kept in the box: the warning about endometrial (uterine lining) cancer for systemic estrogen-alone products. Estrogen taken without a progestogen can overstimulate the uterine lining in a woman who still has her uterus. That risk is real and well established, so it stays.
• Added guidance on timing: systemic products now carry language to consider starting therapy before age 60 or within 10 years of menopause onset. The FDA's November announcement described this as its recommendation, and the updated Bijuva label states it directly in its dosing section.
• Dropped the old "lowest dose for the shortest time" language, according to The Medical Letter's review of the changes, and added Women's Health Initiative data for women aged 50 to 59.

The risks themselves are still on the label. The updated Bijuva label still discusses blood clots, stroke, heart disease and breast cancer findings from the Women's Health Initiative. It also still says the product's safety and efficacy for preventing cardiovascular disease or dementia "has not been established."

Which labels have changed so far

The FDA did not change every label at once. It asked manufacturers to submit new labeling, and 29 companies did. On February 12, 2026, the agency approved the first six. As reported by Managed Healthcare Executive, those six were:

The FDA said this batch included at least one product from each of four groups: combined estrogen-progestogen therapy, estrogen-alone therapy, progestogen therapy for women with a uterus who use estrogen, and vaginal estrogen.

The rollout is not finished. When we checked DailyMed (the National Library of Medicine's label database) in October 2026, the Premarin tablet and Prempro labels posted there still showed the older, broader boxed warning. If you want to know what your own product's label says today, ask your pharmacist or look up the current prescribing information.

Why the warning existed: the WHI story

The boxed warning came out of the Women's Health Initiative (WHI), a large set of randomized trials run by the National Institutes of Health.

In 2002, the WHI stopped its estrogen-plus-progestin trial early. The trial had enrolled 16,608 women aged 50 to 79 who took either a daily pill of conjugated equine estrogens plus medroxyprogesterone acetate or a placebo. After an average of 5.2 years, the safety board found that invasive breast cancer had crossed a pre-set stopping boundary, and that overall risks outweighed benefits. Women on hormones had more heart attacks, strokes, blood clots in the lungs and breast cancers. They also had fewer hip fractures and colorectal cancers.

The results made headlines worldwide, and in the early 2000s the FDA added the boxed warning to menopausal hormone products.

Later WHI analyses added important detail. A 2013 report covering 13 years of follow-up found that most risks and benefits faded after women stopped the pills, though some extra breast cancer risk persisted in the combined-hormone group. In the estrogen-alone trial (women who had had a hysterectomy), breast cancer was not increased. Younger women aged 50 to 59 had more favorable results on some outcomes than older women.

Why the warning was criticized

Critics had argued for years that a warning built on one study design was being applied to every woman and every product. The FDA's own November 2025 announcement made several of these points:

• The women were older. The average WHI participant was 63, more than a decade past the typical age of menopause. Most women who seek HRT for hot flashes are in their late 40s or 50s.
• One formulation was tested. WHI studied one oral estrogen and one synthetic progestin. Patches, gels, micronized progesterone and low-dose vaginal products were never tested in the trial.
• Absolute risks were small in younger women. Relative risk numbers sound alarming. Absolute numbers tell you how many extra events actually happen.

The new Bijuva label lays out the WHI estrogen-plus-progestin numbers for women aged 50 to 59:

Events per 10,000 women per year. Source: Bijuva prescribing information, Warnings and Precautions.

Those are real differences, and blood clots stand out. But they are measured per 10,000 women per year, and several of them were not statistically significant in this age group.

The strongest critique was about vaginal estrogen. Low-dose vaginal products treat dryness, painful sex and urinary symptoms with very little estrogen reaching the bloodstream. Yet they carried the same black box as high-dose pills. The Menopause Society agreed with removing that warning, saying it "may have been a deterrent to the use of the low-dose vaginal estrogen," which it called safe and effective. The president of the American College of Obstetricians and Gynecologists (ACOG) also supported the change, while noting that systemic estrogen has a different safety profile than low-dose vaginal estrogen.

The case against the FDA's move

Not everyone agrees the FDA got this right. The objections fall into three groups.

The process. The FDA relied on a literature review, an expert panel in July 2025 and a public comment period instead of a formal advisory committee. In a 2026 JAMA Viewpoint titled "Menopausal Hormone Labels Should Rely on Evidence, Not Opinion," members of the WHI's own data and safety monitoring board said they support reassessing the warnings but raised concerns about how the decision was made. According to CNN's reporting, four major medical groups (ACOG, The Menopause Society, the American Association of Clinical Endocrinology and the Endocrine Society) said they were not consulted beforehand.

The science on oral hormones. The WHI investigators' statement says no new large randomized trial has changed the balance of risks and benefits for oral hormone therapy. It notes that oral hormones increased stroke and blood clots, did not prevent heart attacks in women aged 50 to 79, and that combined estrogen plus progestin increased breast cancer risk regardless of age. Some menopause specialists quoted by CNN said they would have preferred a narrower change, keeping a warning for systemic pills while dropping it for vaginal estrogen.

Overselling benefits. Some public statements around the announcement talked about hormones preventing heart disease and dementia and extending life. Cardiologists and patient-safety advocates pushed back, noting that those claims go beyond what randomized trials have shown and beyond the approved uses.

There is one point nearly everyone agrees on: the label change does not apply to women who have had breast cancer. The American Society of Clinical Oncology (ASCO) stated that systemic hormone therapy "remains contraindicated" for people who previously had breast cancer, particularly hormone receptor-positive disease. ASCO added that low-dose vaginal estrogen can still be an option for survivors whose symptoms don't respond to non-hormonal treatments, after discussion with their oncology team.

Our take: removing the box from low-dose vaginal estrogen was overdue. For systemic hormones, the change is defensible for healthy women near menopause, but it is a judgment call, and reasonable experts disagree.

What the change does not mean

It is easy to read "black box removed" as "proven safe for everyone." That is not what happened.

• HRT is not heart or brain protection. The new labels still say safety and efficacy for preventing cardiovascular disease or dementia have not been established. WHI's position remains that oral hormone therapy "should not be used for chronic disease prevention."
• Timing still matters. The Menopause Society's position is that for healthy women under 60 or within 10 years of menopause, the benefit-risk ratio is favorable for bothersome hot flashes and preventing bone loss. For women who start more than 10 years after menopause or after 60, it appears less favorable because absolute risks of heart disease, stroke, blood clots and dementia are higher.
• The risks are still listed. Blood clots, stroke and breast cancer findings are now in Warnings and Precautions instead of a black box. Your clinician should still go over them.
• Endometrial protection still matters. If you have a uterus and use systemic estrogen, you generally need a progestogen too.
• It is not about compounded hormones. The label change applies to FDA-approved products. Compounded hormone preparations are not FDA-approved and were not part of this review.
• It is not an anti-aging or weight-loss approval. For what HRT can and cannot do for weight, see Hormones and Weight: What HRT Can — and Cannot — Do.

Is HRT safe now? Who is a good candidate

"Safe" depends on who you are. The label change makes it easier to have an honest conversation. It does not replace one.

You may be a reasonable candidate for systemic HRT if you:

• have moderate to severe hot flashes or night sweats that disrupt sleep, work or quality of life;
• are under 60 or within about 10 years of your last period;
• have no history of breast or endometrial cancer, blood clots, stroke, heart attack, active liver disease or unexplained vaginal bleeding; and
• understand the trade-offs and want to try it.

Low-dose vaginal estrogen is a separate conversation. It may be reasonable for genitourinary symptoms at any age after menopause, even for many women who are not candidates for systemic therapy.

What if you are over 60 or more than 10 years past menopause? You are not automatically excluded. The decision just carries more weight, and route, dose and your heart and clot risk matter more. Women who started HRT earlier and want to continue past 60 should review that decision with their prescriber periodically.

Not sure whether your symptoms are hormonal in the first place? Our article on the signs of hormonal imbalance walks through other causes worth ruling out.

Good questions to bring to a visit:

1. Which risks on the label apply to me, given my age and history?
2. Would a patch or gel change my clot risk compared with a pill?
3. Do I need a progestogen?
4. Would vaginal estrogen alone address my symptoms?
5. How and when will we decide whether to keep going?

Frequently asked questions

Is HRT safe now that the black box warning is gone?

For healthy women under 60 or within 10 years of menopause who have bothersome symptoms, major medical societies consider the benefits likely to outweigh the risks. The risks have not disappeared. They moved from the boxed warning into the Warnings and Precautions section, and your personal history determines how much they matter.

Which warning stayed on the label?

The boxed warning about endometrial cancer stays on systemic estrogen-alone products. It applies to women who still have a uterus and take estrogen without a progestogen.

Does the change apply to women over 60?

The label change applies to the products, not to specific ages. But the new labels suggest considering starting systemic therapy before 60 or within 10 years of menopause. Starting later is not forbidden; it means the benefit-risk balance needs a closer look.

Has every hormone product's label been updated?

No. The FDA approved the first six updated labels on February 12, 2026, and said 29 companies had submitted changes. As of October 2026, some labels posted on DailyMed still showed the older boxed warning.

Can breast cancer survivors use HRT now?

ASCO says no for systemic hormones: systemic hormone therapy remains contraindicated after breast cancer, especially hormone receptor-positive disease. Low-dose vaginal estrogen may be an option after discussion with your oncology team.

The bottom line

The FDA's change is real. The old black box treated every woman and every product as if they were the older women in one oral-hormone trial, and it scared many younger women away from an effective treatment for hot flashes and vaginal symptoms. Dropping it for low-dose vaginal estrogen was overdue.

But the risks of systemic hormones did not vanish with the box. Blood clots, stroke and breast cancer are still on the label, HRT is still not a tool for preventing heart disease or dementia, and timing still matters. Some respected experts, including the WHI's own safety board members, think the FDA moved too broadly and too fast.

The practical takeaway: if menopause symptoms are affecting your life, this is a good time to have the conversation with a licensed provider, using your own age, history and goals, not a headline.

Related reading: Testosterone's New Label: What TRAVERSE Showed · Does TRT Cause Infertility? What Men Should Know

Sources

• HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (FDA, Nov. 10, 2025)
• FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (FDA, Feb. 12, 2026)
• FDA Approves Removal of Black Box Warning for Six Menopausal Hormone Therapies (Managed Healthcare Executive, Feb. 13, 2026)
• In Brief: Label Changes for Menopausal Hormone Therapy Products (The Medical Letter, Feb. 16, 2026)
• DailyMed: Bijuva (estradiol and progesterone) prescribing information
• DailyMed: Premarin (conjugated estrogens) tablets prescribing information
• Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321
• Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040
• The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
• The Menopause Society Comments on the FDA Announcement on Hormone Therapy (The Menopause Society)
• News from the WHI Study: statement on FDA labeling changes (Women's Health Initiative)
• Wittes J, Braunwald E, et al. Menopausal Hormone Labels Should Rely on Evidence, Not Opinion. JAMA. 2026;335(14):1201-1202. doi:10.1001/jama.2026.1308
• ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and Its Implications for Cancer Care (The ASCO Post, Dec. 10, 2025)
• US health leaders hailed the benefits of hormone therapy for menopause. Doctors are pushing for balance (CNN, via ABC 17 News, Nov. 12, 2025)

This article is provided for general educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Do not start, stop or change hormone therapy based on a label change or an article; review your own risks with a qualified healthcare professional.

ASK OUR TEAM ABOUT HORMONE OPTIMIZATION FOR WOMEN